AtriCure, Inc. (ATRC) - Stock Analysis
Last updated: Jun 7, 2026
Research Idea
Research content for general circulation. Not individualized advice. Methodology & Disclosures
AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness.
Loading chart data...
AI Analyst Overview
Loading chart data...
Valuation Metrics
Fundamental Analysis
Key Financial Insights: ⢠Liquidity Strength ⢠Margin Improvement ⢠Cash Volatility ATRC has a strong, low-leverage balance sheet and high gross margins, but profitability and cash flow remain inconsistent, making the current valuation look demanding relative to its still-fragile earnings power.
Price Behavior
Key Price Behavior Insights: ⢠Range-bound action ⢠Resistance failures ⢠Support holding Support Level: $25.9-$26.5 Resistance Level: $28.8-$29.0 ATRC was range-bound over the last month, repeatedly stalling near $28.8-$29.0 while holding $25.9-$26.5 support, so momentum is neutral to cautious until it reclaims resistance.
Sentiment & News
Key News Insights: ⢠Product launches ⢠Platform adoption ⢠Conference visibility AtriCure is pointing to continued growth through new product launches, rising EnCompass adoption, and expanding pain and appendage management opportunities.
AI Summary
ATRC is now a âprove-itâ medtech: its strong gross margins and balance sheet buy time, but the stock likely won't re-rate unless management turns recent adoption gains into consistently positive free cash flow before PFA competition and cash-flow volatility undercut the growth story.
Description
AtriCure develops, manufactures and sells surgical systems and devices used to ablate cardiac tissue and intercostal nerves, serving hospitals and cardiac centers in the United States and internationally. Its portfolio includes radiofrequency and cryoablation systems, epicardial appendage occlusion and suture-based closure solutions, and a range of supporting instruments and disposables for electrophysiology and cardiac surgery. The company distributes products through a mix of independent distributors and direct sales teams and is headquartered in Mason, Ohio; it was incorporated in 2000.
Idea History
| Date | Close | Ticker | Company | Summary | Status | P/L |
|---|---|---|---|---|---|---|
| Jan 12 | Jan 19 | ATRC | AtriCure, Inc. | AtriCure exhibits strong short-term growth supported by 16% revenue increase in Q3, positive EBITDA growth, cash flow improvement, clinical pipeline advancements, and strong technical breakout despite near-term technical softness. | Closed | +3.8% |